Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2020-08-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
北京国枫律师事务所关于公司2018年股票期权激励计划之注销股票期权及首次授予股票期权第一个行权期行权条件成就的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2018 stock option incentive plan of Yunnan Watson Biotechnology Co., Ltd. It discusses the cancellation of certain stock options and the achievement of the first exercise period conditions for the initially granted stock options. The document references relevant laws and regulations, details the approval and decision-making procedures, and confirms compliance with regulatory requirements. It is a legal opinion related to stock option incentive plans rather than a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data but focuses on legal compliance and procedural matters related to stock options. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for legal and compliance documents that do not fit other specific categories.
2020-08-14 Chinese
2018年股票期权激励计划首次授予股票期权第一个行权期可行权激励对象名单
Director's Dealing Classification · 95% confidence The document is titled as the "2018 Stock Option Incentive Plan First Grant Stock Option" and lists detailed allocations of stock options to various executives and core personnel. It includes names, positions, number of stock options granted, exercisable options, and remaining unexercised options. The document also notes that major shareholders or their close relatives did not participate in the plan. This is a detailed disclosure of stock option grants and related personnel information, which is typical of a Director's Dealing or insider share transactions report. There is no indication that this is a full annual report, earnings release, or other financial report. It is not a proxy solicitation or AGM material. The document is focused on stock option grants and exercisable shares for executives and key employees, which fits the definition of Director's Dealing (DIRS). The document length is 6688 characters, which is substantive and contains detailed data, not just an announcement or summary. Therefore, the best classification is DIRS with high confidence.
2020-08-14 Chinese
第四届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Yunnan Watson Biotechnology Co., Ltd. It details the approval of the 2020 semi-annual report, a special report on the use of raised funds, a profit distribution proposal, and other supervisory board decisions. The document does not contain the full semi-annual report or detailed financial statements but rather the Supervisory Board's review and approval of these reports and proposals. It also references that the full reports are available on an external website (巨潮资讯网). The document length is 3828 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal announcement of supervisory board resolutions and approvals related to interim reports and other corporate matters, not the interim report itself.
2020-08-14 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 2020 年半年度报告摘要' which translates to 'Yunnan Walvax Biotechnology Co., Ltd. 2020 Semi-Annual Report Summary'. It contains detailed financial data for the first half of 2020, including revenue, net profit, earnings per share, and asset information. It also discusses operational highlights, product development, shareholder information, and changes in accounting policies. The document is about a half-year period and includes substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is 6738 characters, which is sufficient for a substantive report rather than a brief announcement. There is no indication that this is a full annual report (10-K) or just a summary or announcement. Hence, the classification is IR with high confidence. H1 2020
2020-08-14 Chinese
2020年半年度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (469 characters) from a company about the disclosure of its 2020 half-year report (semi-annual report). It states that the 2020 half-year report and its summary were approved on August 13, 2020, and published on August 15, 2020, on an official disclosure website. The document itself does not contain the actual financial data or the full report but serves as a notification to investors to review the report elsewhere. According to the 'MENU VS MEAL' rule, such a short announcement that informs about the publication of a report without including the report itself should be classified as a Report Publication Announcement (RPA).
2020-08-14 Chinese
华创证券有限责任公司关于公司部分募集资金投资项目结项并将项目结余募集资金永久补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the completion of certain fundraising investment projects and the permanent supplementation of working capital with the remaining raised funds by Yunnan Watson Biotechnology Co., Ltd. It references regulatory guidelines related to fundraising management, details the use and management of raised funds, and includes approvals from the board, supervisory committee, and independent directors. The document is not a full annual or interim financial report, nor is it a simple announcement. It is a specialized report focused on the audit and verification of fundraising project completion and fund usage, which aligns with the definition of an Audit Report / Information (AR). The document length (6419 characters) and content support this classification rather than a Regulatory Filing or Report Publication Announcement. H1 2020
2020-08-14 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.